AFMD Bleeds On Clinical Hold, BHC Gets FDA Nod, MNLO Disappoints

Today's Daily Dose brings you news about clinical hold on Affimed's AFM11 phase I program; Altimmune's $25 million registered direct offering; FDA approval of Bausch Health's BRYHALI Lotion; Menlo's disappointing phase II trial results of Serlopitant and Recro Pharma's anticipated make or break event.

from RTT - Biotech https://ift.tt/2IIjaq5
via IFTTT